(NASDAQ: MXCT) Maxcyte's forecast annual revenue growth rate of 11.43% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.42%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.06%.
Maxcyte's revenue in 2026 is $32,287,000.On average, 9 Wall Street analysts forecast MXCT's revenue for 2026 to be $3,394,900,029, with the lowest MXCT revenue forecast at $3,205,401,791, and the highest MXCT revenue forecast at $3,583,005,685. On average, 9 Wall Street analysts forecast MXCT's revenue for 2027 to be $4,104,688,228, with the lowest MXCT revenue forecast at $3,663,775,426, and the highest MXCT revenue forecast at $4,544,101,326.
In 2028, MXCT is forecast to generate $4,774,520,043 in revenue, with the lowest revenue forecast at $4,102,760,038 and the highest revenue forecast at $5,434,175,299.